Adaptive Biotechnologies (ADPT) Share-based Compensation (2018 - 2026)

Adaptive Biotechnologies has disclosed Share-based Compensation across 9 years of filings, most recently posting $11.1 million for Q2 2026.

• In Q2 2026, Share-based Compensation fell 16.77% year-over-year to $11.1 million; the TTM figure through Jun 2026 stood at $49.1 million (down 5.27% YoY), while the FY2025 annual figure was $56.1 million, up 4.61% from the prior year.
• Share-based Compensation came in at $11.1 million for Q2 2026 at Adaptive Biotechnologies, down from $11.9 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $17.3 million in Q2 2023 to a low of $11.1 million in Q2 2026.
• Average Share-based Compensation over 5 years is $13.9 million, with a median of $14.2 million recorded in 2022.
• Year-over-year, Share-based Compensation climbed 20.97% in 2023 and dropped 25.29% in 2024.
• Over 5 years, Share-based Compensation stood at $14.3 million in 2022, then increased by 8.83% to $15.6 million in 2023, then fell by 17.51% to $12.8 million in 2024, then decreased by 0.87% to $12.7 million in 2025, then slipped by 12.59% to $11.1 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $11.1 million in Q2 2026, $11.9 million in Q1 2026, and $12.7 million in Q4 2025.